Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 790 entries
Sorted by: Best Match Show Resources per page
Prostate cancer: Potential of PARP inhibition plus ADT in prostate cancer.

Nature reviews. Urology

Kelsey R.
PMID: 28926548
Nat Rev Urol. 2017 Nov;14(11):640. doi: 10.1038/nrurol.2017.156. Epub 2017 Sep 19.

No abstract available.

Cite
Kelsey R. Prostate cancer: Potential of PARP inhibition plus ADT in prostate cancer. Nat Rev Urol. 2017;14(11):640doi: 10.1038/nrurol.2017.156.
Kelsey, R. (2017). Prostate cancer: Potential of PARP inhibition plus ADT in prostate cancer. Nature reviews. Urology, 14(11), 640. https://doi.org/10.1038/nrurol.2017.156
Kelsey, Rebecca. "Prostate cancer: Potential of PARP inhibition plus ADT in prostate cancer." Nature reviews. Urology vol. 14,11 (2017): 640. doi: https://doi.org/10.1038/nrurol.2017.156
Kelsey R. Prostate cancer: Potential of PARP inhibition plus ADT in prostate cancer. Nat Rev Urol. 2017 Nov;14(11):640. doi: 10.1038/nrurol.2017.156. Epub 2017 Sep 19. PMID: 28926548.
Copy Download .nbib Format: NLM
Prostate cancer: Resveratrol inhibits the AR.

Nature reviews. Urology

Fenner A.
PMID: 28976500
Nat Rev Urol. 2017 Nov;14(11):642. doi: 10.1038/nrurol.2017.159. Epub 2017 Oct 04.

No abstract available.

Cite
Fenner A. Prostate cancer: Resveratrol inhibits the AR. Nat Rev Urol. 2017;14(11):642doi: 10.1038/nrurol.2017.159.
Fenner, A. (2017). Prostate cancer: Resveratrol inhibits the AR. Nature reviews. Urology, 14(11), 642. https://doi.org/10.1038/nrurol.2017.159
Fenner, Annette. "Prostate cancer: Resveratrol inhibits the AR." Nature reviews. Urology vol. 14,11 (2017): 642. doi: https://doi.org/10.1038/nrurol.2017.159
Fenner A. Prostate cancer: Resveratrol inhibits the AR. Nat Rev Urol. 2017 Nov;14(11):642. doi: 10.1038/nrurol.2017.159. Epub 2017 Oct 04. PMID: 28976500.
Copy Download .nbib Format: NLM
Sexual dysfunction: Shockwaves for erectile dysfunction.

Nature reviews. Urology

Kelsey R.
PMID: 26718457
Nat Rev Urol. 2016 Feb;13(2):63. doi: 10.1038/nrurol.2015.310. Epub 2015 Dec 31.

No abstract available.

Cite
Kelsey R. Sexual dysfunction: Shockwaves for erectile dysfunction. Nat Rev Urol. 2015;13(2):63doi: 10.1038/nrurol.2015.310.
Kelsey, R. (2016). Sexual dysfunction: Shockwaves for erectile dysfunction. Nature reviews. Urology, 13(2), 63. https://doi.org/10.1038/nrurol.2015.310
Kelsey, Rebecca. "Sexual dysfunction: Shockwaves for erectile dysfunction." Nature reviews. Urology vol. 13,2 (2016): 63. doi: https://doi.org/10.1038/nrurol.2015.310
Kelsey R. Sexual dysfunction: Shockwaves for erectile dysfunction. Nat Rev Urol. 2016 Feb;13(2):63. doi: 10.1038/nrurol.2015.310. Epub 2015 Dec 31. PMID: 26718457.
Copy Download .nbib Format: NLM
Kidney cancer: Quality-of-life outcomes in patients with small renal masses.

Nature reviews. Urology

Matin SF.
PMID: 27400666
Nat Rev Urol. 2016 Aug;13(8):443-4. doi: 10.1038/nrurol.2016.124. Epub 2016 Jul 12.

No abstract available.

Cite
Matin SF. Kidney cancer: Quality-of-life outcomes in patients with small renal masses. Nat Rev Urol. 2016;13(8):443-4doi: 10.1038/nrurol.2016.124.
Matin, S. F. (2016). Kidney cancer: Quality-of-life outcomes in patients with small renal masses. Nature reviews. Urology, 13(8), 443-4. https://doi.org/10.1038/nrurol.2016.124
Matin, Surena F. "Kidney cancer: Quality-of-life outcomes in patients with small renal masses." Nature reviews. Urology vol. 13,8 (2016): 443-4. doi: https://doi.org/10.1038/nrurol.2016.124
Matin SF. Kidney cancer: Quality-of-life outcomes in patients with small renal masses. Nat Rev Urol. 2016 Aug;13(8):443-4. doi: 10.1038/nrurol.2016.124. Epub 2016 Jul 12. PMID: 27400666.
Copy Download .nbib Format: NLM
Prostate cancer: The importance of the mitochondrial genome.

Nature reviews. Urology

Thoma C.
PMID: 29039419
Nat Rev Urol. 2017 Dec;14(12):701. doi: 10.1038/nrurol.2017.174. Epub 2017 Oct 17.

No abstract available.

Cite
Thoma C. Prostate cancer: The importance of the mitochondrial genome. Nat Rev Urol. 2017;14(12):701doi: 10.1038/nrurol.2017.174.
Thoma, C. (2017). Prostate cancer: The importance of the mitochondrial genome. Nature reviews. Urology, 14(12), 701. https://doi.org/10.1038/nrurol.2017.174
Thoma, Clemens. "Prostate cancer: The importance of the mitochondrial genome." Nature reviews. Urology vol. 14,12 (2017): 701. doi: https://doi.org/10.1038/nrurol.2017.174
Thoma C. Prostate cancer: The importance of the mitochondrial genome. Nat Rev Urol. 2017 Dec;14(12):701. doi: 10.1038/nrurol.2017.174. Epub 2017 Oct 17. PMID: 29039419.
Copy Download .nbib Format: NLM
Kidney cancer: Systemic therapy--differentiating the achievable from the achieved.

Nature reviews. Urology

Mehrazin R, Galsky MD.
PMID: 25600095
Nat Rev Urol. 2015 Mar;12(3):128-9. doi: 10.1038/nrurol.2014.358. Epub 2015 Jan 20.

No abstract available.

Cite
Mehrazin R, Galsky MD. Kidney cancer: Systemic therapy--differentiating the achievable from the achieved. Nat Rev Urol. 2015;12(3):128-9doi: 10.1038/nrurol.2014.358.
Mehrazin, R., & Galsky, M. D. (2015). Kidney cancer: Systemic therapy--differentiating the achievable from the achieved. Nature reviews. Urology, 12(3), 128-9. https://doi.org/10.1038/nrurol.2014.358
Mehrazin, Reza, and Galsky, Matthew D. "Kidney cancer: Systemic therapy--differentiating the achievable from the achieved." Nature reviews. Urology vol. 12,3 (2015): 128-9. doi: https://doi.org/10.1038/nrurol.2014.358
Mehrazin R, Galsky MD. Kidney cancer: Systemic therapy--differentiating the achievable from the achieved. Nat Rev Urol. 2015 Mar;12(3):128-9. doi: 10.1038/nrurol.2014.358. Epub 2015 Jan 20. PMID: 25600095.
Copy Download .nbib Format: NLM
Pain: Chondroitin sulfate is superior to hyaluronic acid.

Nature reviews. Urology

Sidaway P.
PMID: 28561812
Nat Rev Urol. 2017 Jul;14(7):391. doi: 10.1038/nrurol.2017.86. Epub 2017 May 31.

No abstract available.

Cite
Sidaway P. Pain: Chondroitin sulfate is superior to hyaluronic acid. Nat Rev Urol. 2017;14(7):391doi: 10.1038/nrurol.2017.86.
Sidaway, P. (2017). Pain: Chondroitin sulfate is superior to hyaluronic acid. Nature reviews. Urology, 14(7), 391. https://doi.org/10.1038/nrurol.2017.86
Sidaway, Peter. "Pain: Chondroitin sulfate is superior to hyaluronic acid." Nature reviews. Urology vol. 14,7 (2017): 391. doi: https://doi.org/10.1038/nrurol.2017.86
Sidaway P. Pain: Chondroitin sulfate is superior to hyaluronic acid. Nat Rev Urol. 2017 Jul;14(7):391. doi: 10.1038/nrurol.2017.86. Epub 2017 May 31. PMID: 28561812.
Copy Download .nbib Format: NLM
Kidney cancer: New AUA guideline tackles follow-up monitoring of small renal masses.

Nature reviews. Urology

Payton S.
PMID: 23712208
Nat Rev Urol. 2013 Jul;10(7):367. doi: 10.1038/nrurol.2013.119. Epub 2013 May 28.

No abstract available.

Cite
Payton S. Kidney cancer: New AUA guideline tackles follow-up monitoring of small renal masses. Nat Rev Urol. 2013;10(7):367doi: 10.1038/nrurol.2013.119.
Payton, S. (2013). Kidney cancer: New AUA guideline tackles follow-up monitoring of small renal masses. Nature reviews. Urology, 10(7), 367. https://doi.org/10.1038/nrurol.2013.119
Payton, Sarah. "Kidney cancer: New AUA guideline tackles follow-up monitoring of small renal masses." Nature reviews. Urology vol. 10,7 (2013): 367. doi: https://doi.org/10.1038/nrurol.2013.119
Payton S. Kidney cancer: New AUA guideline tackles follow-up monitoring of small renal masses. Nat Rev Urol. 2013 Jul;10(7):367. doi: 10.1038/nrurol.2013.119. Epub 2013 May 28. PMID: 23712208.
Copy Download .nbib Format: NLM
Bladder cancer: Predicting response to BCG.

Nature reviews. Urology

Payton S.
PMID: 21670751
Nat Rev Urol. 2011 Jun 14;8(7):355. doi: 10.1038/nrurol.2011.82.

No abstract available.

Cite
Payton S. Bladder cancer: Predicting response to BCG. Nat Rev Urol. 2011;8(7):355doi: 10.1038/nrurol.2011.82.
Payton, S. (2011). Bladder cancer: Predicting response to BCG. Nature reviews. Urology, 8(7), 355. https://doi.org/10.1038/nrurol.2011.82
Payton, Sarah. "Bladder cancer: Predicting response to BCG." Nature reviews. Urology vol. 8,7 (2011): 355. doi: https://doi.org/10.1038/nrurol.2011.82
Payton S. Bladder cancer: Predicting response to BCG. Nat Rev Urol. 2011 Jun 14;8(7):355. doi: 10.1038/nrurol.2011.82. PMID: 21670751.
Copy Download .nbib Format: NLM
Renal preservation improves cardiac and overall survival.

Nature reviews. Urology

Groves-Kirkby N.
PMID: 20458800
Nat Rev Urol. 2010 May;7(5):237. doi: 10.1038/nrurol.2010.52.

No abstract available.

Cite
Groves-Kirkby N. Renal preservation improves cardiac and overall survival. Nat Rev Urol. 2010;7(5):237doi: 10.1038/nrurol.2010.52.
Groves-Kirkby, N. (2010). Renal preservation improves cardiac and overall survival. Nature reviews. Urology, 7(5), 237. https://doi.org/10.1038/nrurol.2010.52
Groves-Kirkby, Nick. "Renal preservation improves cardiac and overall survival." Nature reviews. Urology vol. 7,5 (2010): 237. doi: https://doi.org/10.1038/nrurol.2010.52
Groves-Kirkby N. Renal preservation improves cardiac and overall survival. Nat Rev Urol. 2010 May;7(5):237. doi: 10.1038/nrurol.2010.52. PMID: 20458800.
Copy Download .nbib Format: NLM
Laparoscopic AUS for female SUI.

Nature reviews. Urology

Warde N.
PMID: 20397281
Nat Rev Urol. 2010 Apr;7(4):178. doi: 10.1038/nrurol.2010.32.

No abstract available.

Cite
Warde N. Laparoscopic AUS for female SUI. Nat Rev Urol. 2010;7(4):178doi: 10.1038/nrurol.2010.32.
Warde, N. (2010). Laparoscopic AUS for female SUI. Nature reviews. Urology, 7(4), 178. https://doi.org/10.1038/nrurol.2010.32
Warde, Nick. "Laparoscopic AUS for female SUI." Nature reviews. Urology vol. 7,4 (2010): 178. doi: https://doi.org/10.1038/nrurol.2010.32
Warde N. Laparoscopic AUS for female SUI. Nat Rev Urol. 2010 Apr;7(4):178. doi: 10.1038/nrurol.2010.32. PMID: 20397281.
Copy Download .nbib Format: NLM
Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease.

Nature reviews. Urology

Payton S.
PMID: 20545033
Nat Rev Urol. 2010 Jun;7(6):300. doi: 10.1038/nrurol.2010.69.

No abstract available.

Cite
Payton S. Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease. Nat Rev Urol. 2010;7(6):300doi: 10.1038/nrurol.2010.69.
Payton, S. (2010). Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease. Nature reviews. Urology, 7(6), 300. https://doi.org/10.1038/nrurol.2010.69
Payton, Sarah. "Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease." Nature reviews. Urology vol. 7,6 (2010): 300. doi: https://doi.org/10.1038/nrurol.2010.69
Payton S. Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease. Nat Rev Urol. 2010 Jun;7(6):300. doi: 10.1038/nrurol.2010.69. PMID: 20545033.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 790 entries